Interview with SIMRIS GROUP CEO Julian Read about the venture into ADCs, the CDMO deal with Lonza Ltd and where he expects that Simris will be in 3-5 years.
READ OUR MOST RECENT EQUITY RESEARCH ON SIMRIS GROUP HERE
SIMRIS GROUP: Lonza partnership brings ADC platform deals closer
The strategic partnership with Lonza puts Simris in a stronger position going forward as it both validates Simris IP in the high value Antibody-Drug Conjugate (ADC) space and moves the company closer to licensing deals, where we see opportunities for large revenues even in the short term. Encouraged by the deal, we continue to find support for a fair value of SEK 170-230m, which translates to SEK 0.94-1.28 per share in 12-24 months.
Andreas Eriksson & Johan Widmark | 2023-03-06 12:00
This commissioned research report is for informational purposes only and is to be considered marketing communication. This research report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and Emergers is not subject to any prohibition on dealing ahead of the dissemination of investment research. This research does not constitute investment advice and is not a solicitation to buy shares. For more information, please refer to disclaimer.
DISCLAIMER
